Reporting of health equity considerations in cluster and individually randomized trials
Date
2020-04-03
Journal Title
Journal ISSN
Volume Title
Publisher
BMC (part of Springer Nature)
Abstract
Background: The randomized controlled trial (RCT) is considered the gold standard study design to inform
decisions about the effectiveness of interventions. However, a common limitation is inadequate reporting of the
applicability of the intervention and trial results for people who are “socially disadvantaged” and this can affect
policy-makers’ decisions. We previously developed a framework for identifying health-equity-relevant trials, along
with a reporting guideline for transparent reporting. In this study, we provide a descriptive assessment of healthequity
considerations in 200 randomly sampled equity-relevant trials.
Methods: We developed a search strategy to identify health-equity-relevant trials published between 2013 and
2015. We randomly sorted the 4316 records identified by the search and screened studies until 100 individually
randomized (RCTs) and 100 cluster randomized controlled trials (CRTs) were identified. We developed and pilottested
a data extraction form based on our initial work, to inform the development of our reporting guideline for
equity-relevant randomized trials.
Results: In total, 39 trials (20%) were conducted in a low- and middle-income country and 157 trials (79%) in a
high-income country focused on socially disadvantaged populations (78% CRTs, 79% RCTs). Seventy-four trials (37%)
reported a subgroup analysis across a population characteristic associated with disadvantage (25% CRT, 49% RCTs),
with 19% of included studies reporting subgroup analyses across sex, 9% across race/ethnicity/culture, and 4%
across socioeconomic status. No subgroup analyses were reported for place of residence, occupation, religion,
education, or social capital. One hundred and forty-one trials (71%) discussed the applicability of their results to one
or more socially disadvantaged populations (68% of CRT, 73% of RCT).
Discussion: In this set of trials, selected for their relevance to health equity, data that were disaggregated for
socially disadvantaged populations were rarely reported. We found that even when the data are available,
opportunities to analyze health-equity considerations are frequently missed. The recently published equity
extension of the Consolidated Reporting Standards for Randomized Trials (CONSORT-Equity) may help improve
delineation of hypotheses related to socially disadvantaged populations, and transparency and completeness of
reporting of health-equity considerations in RCTs. This study can serve as a baseline assessment of the reporting of
equity considerations.
Description
CITATION: Petkovic, J., et al. 2020. Reporting of health equity considerations in cluster and individually randomized trials. Trials, 21:308, doi:10.1186/s13063-020-4223-5.
The original publication is available at https://trialsjournal.biomedcentral.com
The original publication is available at https://trialsjournal.biomedcentral.com
Keywords
Health services accessibility, Medical care -- Supply and demand, Clinical trials
Citation
Petkovic, J., et al. 2020. Reporting of health equity considerations in cluster and individually randomized trials. Trials, 21:308, doi:10.1186/s13063-020-4223-5